Literature DB >> 22285632

Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study.

Mélanie Drolet1, Myron J Levin, Kenneth E Schmader, Robert Johnson, Michael N Oxman, David Patrick, Simon Olivier Fournier, James A Mansi, Marc Brisson.   

Abstract

We conducted a prospective multi-center study to assess productivity loss associated with herpes zoster (HZ) and postherpetic neuralgia (PHN). From 10/2005 to 07/2006, we recruited immunocompetent subjects aged ≥50 years with HZ within 14 days of rash onset across Canada. Of the 249 patients recruited, 88 were employed. Data on employment status, absences from work, reasons for absence and effectiveness at work were documented at recruitment, 7-14-21-30-60-90-120-150 and 180 days later. The majority (64%) of employed subjects missed work because of HZ and 76% reported decreased effectiveness at work (i.e. presenteeism) because of HZ/PHN. Mean hours of absenteeism and presenteeism per working individual were 27 and 34 h, respectively. Pain severity and duration were associated with greater productivity loss. These results provide new information about the burden of HZ and PHN, which is useful for public health planning and cost-effectiveness analyses of HZ vaccination among individuals of working age. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22285632     DOI: 10.1016/j.vaccine.2012.01.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

Review 1.  Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience.

Authors:  Giovanni Gabutti; Paolo Bonanni; Michele Conversano; Guido Fanelli; Elisabetta Franco; Donato Greco; Giancarlo Icardi; Marzia Lazzari; Alessandro Rossi; Silvestro Scotti; Antonio Volpi
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

2.  Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

Authors:  Phuc Le; Michael B Rothberg
Journal:  JAMA Intern Med       Date:  2018-02-01       Impact factor: 21.873

3.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12

4.  Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.

Authors:  Emmanuelle Préaud; Mathieu Uhart; Katharina Böhm; Pamela Aidelsburger; Delphine Anger; Florence Bianic; Nathalie Largeron
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Burden of herpes zoster and post-herpetic neuralgia in Sweden.

Authors:  Jonas Nilsson; Tobias Cassel; Lars Lindquist
Journal:  BMC Infect Dis       Date:  2015-05-22       Impact factor: 3.090

6.  Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States.

Authors:  Jose A Suaya; Shih-Yin Chen; Qian Li; Stuart J Burstin; Myron J Levin
Journal:  Open Forum Infect Dis       Date:  2014-08-02       Impact factor: 3.835

Review 7.  Assessment of vaccine candidates for persons aged 50 and older: a review.

Authors:  Renske Eilers; Paul F M Krabbe; Ted G A van Essen; Anita Suijkerbuijk; Alies van Lier; Hester E de Melker
Journal:  BMC Geriatr       Date:  2013-04-15       Impact factor: 3.921

8.  Incidence of herpes zoster in patients with altered immune function.

Authors:  S-Y Chen; J A Suaya; Q Li; C M Galindo; D Misurski; S Burstin; M J Levin
Journal:  Infection       Date:  2013-11-10       Impact factor: 3.553

9.  Herpes zoster surveillance using electronic databases in the Valencian Community (Spain).

Authors:  Nuria Morant-Talamante; Javier Diez-Domingo; Sergio Martínez-Úbeda; Joan Puig-Barberá; Sara Alemán-Sánchez; Lina Pérez-Breva
Journal:  BMC Infect Dis       Date:  2013-10-05       Impact factor: 3.090

Review 10.  Vaccination against herpes zoster in developed countries: state of the evidence.

Authors:  Mélanie Drolet; Michael N Oxman; Myron J Levin; Kenneth E Schmader; Robert W Johnson; David Patrick; James A Mansi; Marc Brisson
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.